Critically analyse how the culture of self-medication and weak prescription enforcement in India poses a threat to public health, with special reference to the rise of affordable l

Introduction

India’s expanding access to affordable “lifestyle drugs” (e.g., weight-loss agents, hormonal therapies, antidepressants) is colliding with a culture of self-medication and weak prescription enforcement, creating a silent but systemic public health risk.

Body

The drivers are structural. Easy over-the-counter access despite Schedule H/H1 restrictions, proliferation of online pharmacies, and low doctor-to-population ratios encourage bypassing formal care. High out-of-pocket expenditure (~50% of health spending) and aggressive marketing further nudge consumers toward self-use. Lifestyle drugs amplify this trend because they promise quick, visible benefits, often shaped by social media and wellness narratives.

The consequences are serious. Unsupervised use leads to adverse drug reactions and drug interactions, especially with chronic conditions. For instance, misuse of GLP-1 agonists (semaglutide) can cause complications without medical screening; hormonal drugs may disrupt endocrine balance. Weak stewardship also fuels antimicrobial resistance (AMR)—India already bears one of the highest AMR burdens globally. Public health systems face distorted demand, while irrational use increases long-term costs due to complications and hospitalisations. It also widens inequality, as informed urban users benefit while vulnerable groups face higher risks.

Regulatory gaps persist. Enforcement of the Drugs and Cosmetics Act, 1940 is uneven across states; pharmacovigilance (PvPI) remains underutilised; and e-prescription tracking is limited. While initiatives like Ayushman Bharat and Jan Aushadhi improve access, they do not directly curb irrational use.

Conclusion / Way Forward

A multi-pronged response is essential: strict enforcement of prescription-only norms, integration of e-prescriptions with pharmacy audits, and tighter regulation of e-pharmacies. Expand public awareness campaigns, strengthen primary care (HWCs) to reduce self-care reliance, and incentivise generic prescribing with clinical guidelines. Robust pharmacovigilance and AMR action plans must be scaled up. Balancing access with accountability is key to ensuring that affordable drugs translate into better health outcomes, not hidden harms.